Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports

Author:

Kyriakoulis Konstantinos G.1ORCID,Kollias Anastasios1ORCID,Kyriakoulis Ioannis G .2ORCID,Kyprianou Ioanna A.3ORCID,Papachrysostomou Chrysso4,Makaronis Panagiotis4,Kotronias Rafail A.5ORCID,Terentes-Printzios Dimitrios6ORCID,Toskas Ioannis7,Mikhailidis Dimitri P.8ORCID

Affiliation:

1. Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Greece

2. Faculty of Medicine, School of Health Science, University of Thessaly, Larissa, Greece

3. School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

4. Department of Cardiology, General Hospital of Athens “G. Gennimatas”, Athens, Greece

5. Department of Cardiovascular Medicine, University of Oxford, Oxford, UK

6. Oxford Heart Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK

7. Departmentof Cardiology and Angiology, Faculty of Medicine of the Eberhard Karls University Tübingen, Tübingen, Germany

8. Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), UK

Abstract

Background: Venous thromboembolism (VTE) is common among patients with severe coronavirus disease 2019 (COVID-19). Anticoagulation in hospitalized COVID-19 patients has been associated with survival benefit; however, the optimal thromboprophylaxis strategy has not yet been defined. Objective: To identify published guidance reports by national and international societies regarding thromboprophylaxis strategies in COVID-19 patients in different settings (outpatients, hospitalized, post-discharge). Methods: A systematic review of the literature (Pubmed/EMBASE) was conducted independently by two investigators. Results: Among 1942 initially identified articles, 33 guidance documents were included: 20 published by national and 13 by international societies. These documents provide recommendations mainly for hospitalized (97% of reports) and post-discharge (75%) COVID-19 patients, and less so for outpatients (34%). Thrombotic and bleeding risk stratification prior to any treatment decision is the cornerstone of all suggested thromboprophylaxis strategies; 81% of the documents recommend thromboprophylaxis for all hospitalized patients with a prophylactic dosage of low molecular weight heparin irrespective of VTE risk. Intermediate or therapeutic dose intensity is recommended in high VTE risk patients by 56% and 28% of documents, respectively. Mechanical thromboprophylaxis is suggested in case of high bleeding risk or contraindication to pharmacological thromboprophylaxis (59% of documents). Extended pharmacological thromboprophylaxis is recommended for patients with high VTE risk after hospital discharge (63% of documents). For non-hospitalized outpatients, 28% of documents recommend pharmacological thromboprophylaxis for high VTE risk. Conclusion: The current guidance identifies thromboprophylaxis in COVID-19 patients, especially during hospitalization, as of major importance for the prevention of VTE. Recommendations are derived from limited evidence from observational studies.

Publisher

Bentham Science Publishers Ltd.

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3